TABLE 4.

Liver‐related complications following successful HCV treatment

	Interferon‐cured	DAA‐cured
Number	97	102
Follow‐up since SVR (years)
Median, IQR	16 (14–22)	4 (3–5)
Group total	1626	385
Liver‐related complication after SVR a	3 (3%)	4 (4%) b
Per 100 patient‐years	.2 (95% CI .05–.5)	1.0 (95% CI .3–2.5)
Per 100 patient‐years (only F3/F4 c )	1.0 (95% CI .2–2.7)	2.2 (95% CI .7–5.2)
Hepatocellular carcinoma after SVR	1 (1%)	3 (3%) b
Per 100 patient‐years	.1 (95% CI .003–.3)	.8 (95% CI .2–2.1)
Per 100 patient‐years (only F3/F4 c )	.3 (95% CI .02–1.6)	1.6 (95% CI .4–4.4)
Liver‐related death after SVR	0	1 (1%)
Per 100 patient‐years	0	.3 (95% CI .01–1.3)
Per 100 patient‐years (only F3/F4 c )	0	.5 (95% CI .03–2.7)
All‐cause mortality after SVR	4 (4%)	4 (4%)
Per 100 patient‐years	.2 (95% CI .8–5.9)	1.0 (95% CI .3–2.5)

Data are reported as number (percentage) or incidence (95% confidence interval) unless otherwise noted. CI, confidence interval; DAA, direct‐acting antivirals; HCV, hepatitis C virus; IQR, interquartile range; SVR, sustained virological response.

^aDefined as hepatocellular carcinoma, decompensated cirrhosis or variceal bleeding.

^bOne individual had a liver‐related event prior to SVR (hepatocellular carcinoma), and a recurrent hepatocellular carcinoma following SVR.

^cAdvanced fibrosis or cirrhosis. Defined as a Fibroscan result ≥9.5 kPa or radiological, histological or clinical diagnosis.